UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria
The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as...
| Główni autorzy: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
American Society for Microbiology
2018
|
| _version_ | 1826260418040954880 |
|---|---|
| author | Brunschwig, C Lawrence, N Taylor, D Abay, E Njoroge, M Basarab, GS Le Manach, C Paquet, T Cabrera, D Nchinda, AT de Kock, C Wiesner, L Denti, P Waterson, D Blasco, B Leroy, D Witty, MJ Donini, C Duffy, J Wittlin, S White, KL Charman, SA Jiménez-Díaz, MB Angulo-Barturen, I Herreros, E Gamo, FJ Rochford, R Mancama, D Coetzer, TL van der Watt, ME Reader, J Birkholtz, L-M Marsh, KC Solapure, SM Vanaerschot, M Fidock, DA Fish, PV Siegl, P Smith, DA Wirjanata, G Noviyanti, R Price, RN Marfurt, J Silue, KD Street, LJ Chibale, K |
| author_facet | Brunschwig, C Lawrence, N Taylor, D Abay, E Njoroge, M Basarab, GS Le Manach, C Paquet, T Cabrera, D Nchinda, AT de Kock, C Wiesner, L Denti, P Waterson, D Blasco, B Leroy, D Witty, MJ Donini, C Duffy, J Wittlin, S White, KL Charman, SA Jiménez-Díaz, MB Angulo-Barturen, I Herreros, E Gamo, FJ Rochford, R Mancama, D Coetzer, TL van der Watt, ME Reader, J Birkholtz, L-M Marsh, KC Solapure, SM Vanaerschot, M Fidock, DA Fish, PV Siegl, P Smith, DA Wirjanata, G Noviyanti, R Price, RN Marfurt, J Silue, KD Street, LJ Chibale, K |
| author_sort | Brunschwig, C |
| collection | OXFORD |
| description | The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as solubility and antiplasmodial potency across the parasite lifecycle, leading to the 2-aminopyrazine UCT943. The compound displayed higher asexual blood stage, transmission-blocking, and liver stage activity than MMV048 and was more potent against resistant P. falciparum and P. vivax clinical isolates. Excellent in vitro antiplasmodial activity translated into high efficacy in P. berghei and humanized P. falciparum NOD-scid IL-2Rγnull mouse models. The high passive permeability and high aqueous solubility of UCT943, combined with low to moderate in vitro intrinsic clearance, resulted in sustained exposure and high bioavailability in preclinical species. In addition, the predicted human dose for a curative single administration using monkey and dog pharmacokinetics was low, ranging from 50 to 80 mg. As a next generation Plasmodium PI4K inhibitor, the combined preclinical data suggest that UCT943 has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent and block the transmission of malaria. |
| first_indexed | 2024-03-06T19:05:20Z |
| format | Journal article |
| id | oxford-uuid:14edbcdb-ccd5-434f-ac7a-4c93ad57a0d7 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:05:20Z |
| publishDate | 2018 |
| publisher | American Society for Microbiology |
| record_format | dspace |
| spelling | oxford-uuid:14edbcdb-ccd5-434f-ac7a-4c93ad57a0d72022-03-26T10:22:39ZUCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malariaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:14edbcdb-ccd5-434f-ac7a-4c93ad57a0d7EnglishSymplectic Elements at OxfordAmerican Society for Microbiology2018Brunschwig, CLawrence, NTaylor, DAbay, ENjoroge, MBasarab, GSLe Manach, CPaquet, TCabrera, DNchinda, ATde Kock, CWiesner, LDenti, PWaterson, DBlasco, BLeroy, DWitty, MJDonini, CDuffy, JWittlin, SWhite, KLCharman, SAJiménez-Díaz, MBAngulo-Barturen, IHerreros, EGamo, FJRochford, RMancama, DCoetzer, TLvan der Watt, MEReader, JBirkholtz, L-MMarsh, KCSolapure, SMVanaerschot, MFidock, DAFish, PVSiegl, PSmith, DAWirjanata, GNoviyanti, RPrice, RNMarfurt, JSilue, KDStreet, LJChibale, KThe 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as solubility and antiplasmodial potency across the parasite lifecycle, leading to the 2-aminopyrazine UCT943. The compound displayed higher asexual blood stage, transmission-blocking, and liver stage activity than MMV048 and was more potent against resistant P. falciparum and P. vivax clinical isolates. Excellent in vitro antiplasmodial activity translated into high efficacy in P. berghei and humanized P. falciparum NOD-scid IL-2Rγnull mouse models. The high passive permeability and high aqueous solubility of UCT943, combined with low to moderate in vitro intrinsic clearance, resulted in sustained exposure and high bioavailability in preclinical species. In addition, the predicted human dose for a curative single administration using monkey and dog pharmacokinetics was low, ranging from 50 to 80 mg. As a next generation Plasmodium PI4K inhibitor, the combined preclinical data suggest that UCT943 has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent and block the transmission of malaria. |
| spellingShingle | Brunschwig, C Lawrence, N Taylor, D Abay, E Njoroge, M Basarab, GS Le Manach, C Paquet, T Cabrera, D Nchinda, AT de Kock, C Wiesner, L Denti, P Waterson, D Blasco, B Leroy, D Witty, MJ Donini, C Duffy, J Wittlin, S White, KL Charman, SA Jiménez-Díaz, MB Angulo-Barturen, I Herreros, E Gamo, FJ Rochford, R Mancama, D Coetzer, TL van der Watt, ME Reader, J Birkholtz, L-M Marsh, KC Solapure, SM Vanaerschot, M Fidock, DA Fish, PV Siegl, P Smith, DA Wirjanata, G Noviyanti, R Price, RN Marfurt, J Silue, KD Street, LJ Chibale, K UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria |
| title | UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria |
| title_full | UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria |
| title_fullStr | UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria |
| title_full_unstemmed | UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria |
| title_short | UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria |
| title_sort | uct943 a next generation plasmodium falciparum pi4k inhibitor preclinical candidate for the treatment of malaria |
| work_keys_str_mv | AT brunschwigc uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT lawrencen uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT taylord uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT abaye uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT njorogem uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT basarabgs uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT lemanachc uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT paquett uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT cabrerad uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT nchindaat uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT dekockc uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT wiesnerl uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT dentip uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT watersond uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT blascob uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT leroyd uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT wittymj uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT doninic uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT duffyj uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT wittlins uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT whitekl uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT charmansa uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT jimenezdiazmb uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT angulobartureni uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT herrerose uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT gamofj uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT rochfordr uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT mancamad uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT coetzertl uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT vanderwattme uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT readerj uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT birkholtzlm uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT marshkc uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT solapuresm uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT vanaerschotm uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT fidockda uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT fishpv uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT sieglp uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT smithda uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT wirjanatag uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT noviyantir uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT pricern uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT marfurtj uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT siluekd uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT streetlj uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria AT chibalek uct943anextgenerationplasmodiumfalciparumpi4kinhibitorpreclinicalcandidateforthetreatmentofmalaria |